The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

People are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns. Patients who land in the ER following hallucinogen use have a 21-fold higher risk of developing ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

U.S. stocks rose Monday, led by those seen as benefiting the most from Donald Trump's reelection as president, but drops for ...

Most U.S. stocks rose on Wall Street, but drops for Nvidia and some other heavyweight Big Tech companies kept indexes in ...